BIOCON vs NEULANDLAB: Stock Comparison

Biocon Limited vs Neuland Laboratories Limited

Live data: 22 July 2026, 3:01 PM IST • Source: NSE and company filings

Biocon Limited is the larger company by market capitalisation. Biocon Limited shows a higher dividend yield, while Neuland Laboratories Limited shows a lower P/E, a higher ROE and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Biocon Limited and Neuland Laboratories Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, BIOCON is more favourable on 2 of 13 scored metrics and NEULANDLAB on 11These counts are context-free and are not an overall rating.

Key Differences

Market Cap
BIOCON is the larger company
₹70,989 Cr vs ₹23,702 Cr
P/E Ratio
NEULANDLAB has a lower P/E
66.58x vs 185.25x
P/B Ratio
BIOCON has a lower P/B
2.1x vs 12.93x
EPS
NEULANDLAB has higher earnings per share
₹293.13 vs ₹2.86
Dividend Yield
BIOCON has a higher dividend yield
0.11% vs 0.06%
Revenue Growth (TTM YoY)
NEULANDLAB has faster revenue growth
136.4% vs 2.3%
EPS Growth (TTM YoY)
NEULANDLAB has faster EPS growth
664.4% vs -72.5%
Qtr Sales Growth
NEULANDLAB has stronger quarterly sales growth
136% vs 2.25%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBIOCONNEULANDLAB
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricBIOCONNEULANDLAB
Live Price₹437.75₹18,461
Day Change-0.58%-2.3%
Volume51.58 L14,931
52-Week High₹447.15₹20,089
52-Week Low₹331₹11,500
Distance from 52W High-2.1%-8.1%

Valuation

MetricBIOCONNEULANDLAB
Market Cap₹70,989 Cr₹23,702 Cr
P/E Ratio185.25x66.58x
P/B Ratio2.1x12.93x
EPS₹2.86₹293.13
Book Value₹210.14₹1,460.02
Dividend Yield0.11%0.06%

Growth

MetricBIOCONNEULANDLAB
Revenue Growth (TTM YoY)2.3%136.4%
EPS Growth (TTM YoY)-72.5%664.4%
Qtr Sales Growth2.25%136%
Qtr Profit Growth-62%665%

Profitability & Leverage

MetricBIOCONNEULANDLAB
ROE1.4%21.4%
ROCE3.75%26.6%
Net Margin2.29%17.99%
Operating Margin20.4%28.4%
Debt to Equity0.45x0.16x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricBIOCONNEULANDLAB
Promoter Holding29.73% 0.17 pp32.63%
FII Holding8.16% 0.64 pp20.46% 0.44 pp
DII Holding23.37% 0.7 pp15.84% 1.13 pp
Public Holding23.74% 0.33 pp31.07% 0.69 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Biocon Limited and Neuland Laboratories Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.